OCX - OncoCyte Short-Term Debt to Capital

This price chart on GURU.Markets for OncoCyte Corporation (OCX), which specializes in cancer diagnostics, captures the 0.15 metric. The biopharmaceutical sector relies on steady demand, although sanctions create risks for raw material logistics. Global technological fragmentation hinders data exchange and reagent supplies. Following restructuring, OncoCyte Corporation (OCX) is focusing on direct product sales, expanding its distribution network through major laboratories.

As it advances innovations in molecular diagnostics, OncoCyte Corporation (OCX) faces a rigorous struggle for insurance coverage, necessitating the optimization of liquidity. This ratio compares liabilities with a maturity of up to one year against equity to measure the company's dependence on rapid refinancing amid expensive borrowing; consequently, an increase in current debt under one year relative to equity signals rising financial instability risks to investors.